 Recombinant alpha interferon metastatic renal cell carcinoma cooperative phase II study total evaluable patients advanced renal cell carcinoma IU square meter body surface recombinant alpha interferon times week Cooperative Phase II Study Toxic death terminal renal failure patient toxicities present cases overall response rate months treatment partial response minor response complete responses fifteen months Long-lasting stabilization disease percent